We report a systematic, cellular phenotype-based antimalarial screening of the MMV Pathogen Box 31 collection, which facilitated the identification of specific blockers of late stage intraerythrocytic 32 Plasmodium falciparum maturation. First, from standard growth inhibition asays, we discovered 62 33 additional antimalarials (EC 50 ≤ 10µM) over previously known antimalarial candidates from Pathogen 34 Box. A total of 90 potent molecules (EC 50 ≤ 1µM) were selected for evaluating their stage-specific 35 effects during the intra-erythrocytic development of P. falciparum. None of these molecules had 36 significant effect on ring-trophozoite transition, 10 molecules inhibited trophozoite-schizont transition, 37 and 21 molecules inhibited schizont-ring transition at 1µM. These compounds were further validated 38 in secondary assays by flow cytometry and microscopic imaging of treated cells to prioritize 12 39 molecules as potent and selective blockers of schizont-ring transition. Seven of these were found to 40 strongly inhibit calcium ionophore induced egress of Toxoplasma gondii, a related apicomplexan 41 parasite, suggesting that the inhibitors may be acting via similar mechanism in the two parasites, 42 which can be further exploited for target identification studies. Two of these molecules, with previously 43 unknown mechanism of action, MMV020670 and MMV026356, were found to induce fragmentation of 44 DNA in developing merozoites. Further mechanistic studies would facilitate therapeutic exploitation of 45 these molecules as broadly active inhibitors targeting development and egress of apicomplexan 46 parasites relevant to human health. 47 48 49 Despite technological advancements and improved knowledge on disease manifestation and 69 pathogen biology, progress in therapeutic development has been slower than expected for human 70 infectious diseases affecting the developing world. In addition to limited financial prospects, 71 pharmaceutical companies remain under significant pressure to address high attrition rates. In this 72 context, repurposing of old drugs is becoming a viable alternative through the exploitation of known 73 compounds with established mechanisms thereby shortening the time window between efficacy 74 testing to pharmacophore optimization 1-3 to eventual application. In recent efforts to speed up the 75 process of drug development against various pathogenic diseases, a collaborative model of public-76 private partnerships (PPPs) facilitated through Medicines for Malaria Venture (MMV: mmv.org) was 77 formed. This resulted in well-characterized drug-like small molecule libraries being made accessible 78 to academics worldwide, for the purpose of identifying novel bioactivities against various tropical 79 disease pathogens and conducting focused mechanistic studies. In 2015, the consortium launched 80 the open access "Pathogen Box" consisting of 400 drug-like small molecules, included 26 reference 81 compounds, with confirmed bioactivity against at least one of the neglected disease pathogens 82 (Plasmodium, Mycobacterium, Kinetoplastids, Schistosoma, Cryptosporidium, helminths and dengue 83 virus), 4 as a way to facilitate open-ended drug discovery. 84 85 Open access to the Pathogen Box has led to the discovery of newly identified activities against 86 various pathogens, for example, MMV688934 (Tolfenpyrad) showed activity against the helminth 87 parasite and barber's pole worm 5 while MMV688768 was shown to demonstrate inhibitory activity 88 against Candida albicans biofilm formation 6 . Previously, these molecules were established as 89 inhibitors of kinetoplastid and schistosomiasis 5-6 respectively. However, the latter molecule has been 90 recently documented to have no activity against S. mansoni 7 . Dual activity against Giardia and 91 Cryptosporidium were reported for MMV010576, MMV028694 and MMV676501 that showed ≥ 75% 92 inhibitory efficacy 8 . Several such studies have accelerated the identification of small molecules that 93 are now re-profiled, repurposed and reclassified to show broader inhibitory activities on more than 94 one pathogenic agent 9-12 . 95 96 Plasmodium falciparum is the most virulent human malaria species and is widespread, accounting for 97 99.7% of estimated malaria cases in the African Region, 62.8% in South-East Asia, 69% in Eastern 98 Mediterranean region and 71.9% in Western Pacific region 13-15 . Within the human host, Plasmodium 99 undergoes vastly different developmental changes in liver cells and red blood cells. However, intra-100 erythrocytic (blood stage) development is most obvious during infection and is responsible for 101 malaria-associated pathological outcomes. Over the past several decades, many attempts have been 102 made to eradicate malaria but with limited success due to challenges in the form of drug resistance, 103 changes in vector distribution and density, and improper regulatory framework in many malaria 104 endemic areas. Malaria-endemic regions are rapidly losing affordable and effective therapeutic 105 options, making it necessary to develop new drugs with novel modes of action and molecular targets.
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Magnet purified schizont stage parasites (~42-44 hpi) were treated with selected Pathogen Box 204 molecules at a concentration of 1 µM for 1 h. Following incubation, 5 µM CellROX® Green reagent 205 (Thermo Fisher Scientific, Inc.) was added to the cells and incubated for 30 min in a 5% CO 2 206 incubator at 37° C. The cells were co-stained with Hoechst 33342 during the last 15 min of incubation 207 in MCM at 37° C in dark. The cells were then washed with PBS three times and visualized using a 208 fluorescent microscope (Olympus CKX53 inverted microscope).
209
Assessment of DNA damage using Comet Chip.
210
Alkaline Comet Chip assay was performed as described [21] [22] 
223
Egress inhibition studies in Toxoplasma gondii.
224
Tachyzoite stage RH strain T. gondii were cultured in the laboratory as previously reported 18 . When
225
exposed to the calcium ionophore A23187, intracellular tachyzoites are known to rapidly rupture the 226 parasitophorous vacuole and egress out of the host cells [23] [24] [25] . Here, the ionophore induced egress of 227 T. gondii tachyzoites was performed after treating the parasites with selected inhibitors (at 10 µM for 228 24 h) to assess their effect on the egress process. The time required for vacuole rupture and parasite 229 egress was monitored using a 40X objective fitted to an inverted bright-field microscope (Primo Vert,
230
Zeiss) for a period of 10 min and images were captured at 30 sec intervals. 
260
To first identify all MMV Pathogen Box compounds that possess antimalarial activity, a standard end 261 point growth inhibition assay was performed on blood-stage P. falciparum parasites. Sorbitol 262 synchronized ring stage parasites were treated with all 400 Pathogen Box compounds at 10 µM for 60 263 h and those which inhibited parasite growth by ≥ 80% were selected for EC 50 determination. In the 264 dose assay, the compounds were tested at concentrations ranging from 10 µM to 1 nM. Out of 400
265
Pathogen Box compounds, 162 molecules (~40% hit rate) were found to inhibit growth of blood stage 266 P. falciparum parasites by ≥ 80%. Out of the 125 Pathogen Box compounds with previously reported 267 antimalarial activity, only 100 showed ≥ 80% inhibition of parasite growth (Fig. 1A) , and the remaining 268 25 compounds had varying levels of inhibitory activity, presumably due to differences in the assay 269 conditions 10 or parasitic stages tested. A compilation of screening data is provided in the 270 supplementary information (Supplemental Dataset, S1). Interestingly, 62 compounds, previously
271
shown to be active against other pathogens, were also found to have potent antimalarial activity ( 
303
(20-22 hpi) and schizonts (40 to 42 hpi) -were treated with 1 µM inhibitor and assessed after ~12h 304 treatment for their ability to block stage transition using flow cytometry based detection of the parasite 305 stages ( Fig. 2A) . None of the molecules showed any significant inhibition of ring-trophozoite transition
306
[R→T], which is in line with previous reports suggesting that ring stage parasites are rather resilient to 307 antimalarial compounds [37] [38] . 20 newly identified molecules with EC 50 value ≤ 1 µM ( Fig. 2A 
317
Furthermore, trophozoites are also transcriptionally more active and are engaged in preparation of the 318 parasite cell for daughter cell formation and cell division, which makes them more "target-rich" for 319 small molecule inhibitors [39] [40] . Interestingly, we identified 21 molecules, which had significant effect on
320
[S→R] transition. Among them, MMV021660 is known to inhibit folate pathway in Mycobacterium 41-42 .
321
It is noteworthy that although EC 50 values for some of the newly identified antiplasmodial molecules 
335
we employed two levels of validation using flow cytometry and microscopic examination.
336
Synchronized parasites were allowed to develop into schizont stage (40 to 42 hpi) parasites and then 337 treated with three different concentrations (1, 3, and 10 µM) of the inhibitors in the initial screen. After 12 h treatment (i.e., ~55 hpi) the number of parasites present as newly formed rings and un-ruptured 339 schizonts were scored using flow cytometry. DMSO and E64 were included as negative and positive 340 controls respectively. To observe the parasite cell phenotypic following inhibitor treatment, 341 microscopic examination of Giemsa-stained smears was performed. We observed that 50 of the 162 342 pathogen box molecules showed inhibitory effect of ≥50% in [S→R] transition at 10 µM, which 343 dropped to 38 molecules at 3 µM and 29 molecules at 1 µM (Fig. 2B) 
356
However, parasites treated with MMV026356 or MMV020670 appeared to be unhealthy and dying,
357
indicating that there may be no direct inhibition of egress or invasion process ( Fig. 3C) 
394
treated parasites, we considered an average egress time delay of at least 4 min to assign them as 395 potential egress inhibitors in T. gondii (Fig. 4A) . Interestingly, we identified 7 molecules (MMV020081,
396
MMV085071, MMV024443, MMV026356, MMV020670, MMV006239 and MMV020710) with 397 significant egress-blocking activity, and at least in case of 3 molecules (MMV020670, MMV020081 398 and MMV026356) egress block extended beyond 7 minutes (Fig 4A, highlighted in Fig. 5A) . Following this observation, we performed a 413 quantitative flow cytometry-based ROS assay on these molecules, which indicated that at least 5 of 414 these molecules (MMV006239, MMV020670, MMV026356, MMV024443 and MMV085071) were 415 potent ROS generators (Fig. 5B ).
417
This was an interesting observation, and since increased intracellular ROS can cause DNA damage,
418
we tested this using a comet assay that allows visualization of the extent of DNA damage/break-down 419 following inhibitor treatment. From these experiments, ≥50% DNA damage was observed following 420 treatment with the molecules MMV020670 and MMV026356 (Fig. 5C) , as indicated by comet tail 421 moment at 5 µM drug exposure (Fig. 5D) 
428
[SàR] transition involves sequential preparatory and remodelling events in the parasite, which offers 429 numerous targets for inhibitors. Further mechanistic studies on selected Pathogen Box molecules is 430 needed to fully realize the therapeutic potential of these molecules. Studies on altered gene and 431 protein expression, combined with proteome modification studies can be good starting points for 432 obtaining further insights on the mechanism of these molecules.
434
Conclusions.
435
Growth inhibition studies on blood stage P. falciparum using the MMV Pathogen Box chemical library 
